Latest & greatest articles for ciprofloxacin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ciprofloxacin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ciprofloxacin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ciprofloxacin

1. Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial

Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial 29944651 2018 07 08 1549-1676 15 6 2018 Jun PLoS medicine PLoS Med. Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial. e1002593 10.1371/journal.pmed.1002593 Antibiotic prophylaxis for contacts (...) of meningitis cases is not recommended during outbreaks in the African meningitis belt. We assessed the effectiveness of single-dose oral ciprofloxacin administered to household contacts and in village-wide distributions on the overall attack rate (AR) in an outbreak of meningococcal meningitis. In this 3-arm, open-label, cluster-randomized trial during a meningococcal meningitis outbreak in Madarounfa District, Niger, villages notifying a suspected case were randomly assigned (1:1:1) to standard care

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

2. Ciprofloxacin

Ciprofloxacin Top results for ciprofloxacin - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ciprofloxacin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

3. Ciprofloxacin (Cetraxal) - treatment of acute otitis externa

Ciprofloxacin (Cetraxal) - treatment of acute otitis externa Final Appraisal Recommendation Advice No: 1218 – July 2018 Ciprofloxacin (Cetraxal ® ) 2 mg/ml ear drops solution in a single dose container Limited submission by Aspire Pharma Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1343), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (...) (PAR) and the applicant company’s response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective. This recommendation has been ratified by Welsh Government and will be considered for review every three years. Recommendation of AWMSG Ciprofloxacin (Cetraxal ® ) is recommended as an option for use within NHS Wales for the treatment of acute otitis externa in adults and children older than 1 year with an intact

All Wales Medicines Strategy Group2018

4. Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial

Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial 29946179 2018 06 27 1572-0241 2018 Jun 27 The American journal of gastroenterology Am. J. Gastroenterol. Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. 10.1038/s41395-018-0168-7 For the prevention of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites, norfloxacin 400 mg per day (...) is recommended as a standard regimen. This study aims to investigate whether ciprofloxacin once weekly administration is not inferior to norfloxacin once daily administration for the prevention of SBP. This is an investigator-initiated open-label randomized controlled trial conducted at seven tertiary hospitals in South Korea. Liver cirrhosis patients with ascites were screened, and enrolled in this randomized controlled trial if ascitic protein ≤1.5 g/dL or the presence of history of SBP. Ascitic

EvidenceUpdates2018

5. Ciprofloxacin ear drops (Cetraxal) - acute otitis externa

Ciprofloxacin ear drops (Cetraxal) - acute otitis externa Published 9 April 2018 Product Update: ciprofloxacin ear drops solution, single dose container 2mg/mL (Cetraxal ® ) SMC No 1320/18 Aspire Pharma Limited 9 March 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission (...) ciprofloxacin ear drops (Cetraxal ® ) are accepted for restricted use within NHS Scotland. Indication under review: treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane, caused by ciprofloxacin susceptible microorganisms. SMC restriction: when off-label or unlicensed ciprofloxacin formulations would otherwise be used. Ciprofloxacin eye drops (used off-label) or unlicensed ciprofloxacin ear drops have been in use in NHS Scotland for this indication

Scottish Medicines Consortium2018

6. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis

RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis 29371384 2018 01 26 1399-3003 51 1 2018 Jan The European respiratory journal Eur. Respir. J. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. 1702053 10.1183/13993003.02053-2017 We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI (...) ) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous year and predefined sputum bacteria.Patients were randomised 2:1 to twice-daily ciprofloxacin DPI 32.5 mg or placebo in 14- or 28-day on/off treatment cycles for 48 weeks. Primary end-points were time to first exacerbation and frequency of exacerbations. Enrolling countries and α level split (0.049 and 0.001 for 14- and 28-day cycles, respectively) differed from RESPIRE 1.Patients were randomised

EvidenceUpdates2018

7. Transcriptome Profiling Reveals Interplay of Multifaceted Stress Response in Escherichia coli on Exposure to Glutathione and Ciprofloxacin

Transcriptome Profiling Reveals Interplay of Multifaceted Stress Response in Escherichia coli on Exposure to Glutathione and Ciprofloxacin Transcriptome Profiling Reveals Interplay of Multifaceted Stress Response in Escherichia coli on Exposure to Glutathione and Ciprofloxacin | mSystems Main menu User menu Search Search for this keyword Search for this keyword Editor's Pick Research Article | Molecular Biology and Physiology Transcriptome Profiling Reveals Interplay of Multifaceted Stress (...) Response in Escherichia coli on Exposure to Glutathione and Ciprofloxacin Manish Goswami , Akkipeddi Venkat Satya Surya Narayana Rao Pieter C. Dorrestein , Editor Manish Goswami Molecular Biology Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India Homi Bhabha National Institute, Anushaktinagar, Mumbai, India Akkipeddi Venkat Satya Surya Narayana Rao Molecular Biology Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India Pieter C. Dorrestein University of California, San Diego DOI

mSystems2018 Full Text: Link to full Text with Trip Pro

8. Ciprofloxacin 3mg/mL + dexamethasone 1mg/mL ear drops (Cilodex) - Acute otitis media in patients with tympanostomy tubes (AOMT) and Acute otitis externa

Ciprofloxacin 3mg/mL + dexamethasone 1mg/mL ear drops (Cilodex) - Acute otitis media in patients with tympanostomy tubes (AOMT) and Acute otitis externa Published 10 July 2017 Product Update: ciprofloxacin 3mg/mL + dexamethasone 1mg/mL ear drops (Cilodex ® ) SMC No (1256/17) Novartis Pharmaceuticals UK Ltd 09 June 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use (...) in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission ciprofloxacin+dexamethasone (Cilodex ® ) is accepted for restricted use within NHS Scotland. Indication under review: Treatment of the following infections in adults and children: Acute otitis media in patients with tympanostomy tubes (AOMT) Acute otitis externa SMC restriction: Treatment of acute otitis media in patients with tympanostomy tubes (AOMT). Cilodex ® provides a licensed alternative to “off

Scottish Medicines Consortium2017

9. Ciloxan (Ciprofloxacin) - otitis externa or otitis media

Ciloxan (Ciprofloxacin) - otitis externa or otitis media 1/16 The legally binding text is the original French Version TRANSPARENCY COMMITTEE OPINION 19 October 2011 CILOXAN 3 mg/ml, ear drops, solution B/1 bottle of 5 ml (CIP code: 3601303) Applicant: ALCON FRANCE Ciprofloxacin ATC code: S02AA (antibiotic from the fluoroquinolone family) List I Date of Marketing Authorisation: 28 November 2002, amendment of 14 May 2008 Reason for request: Inclusion on the list of medicines refundable (...) by National Health Insurance and approved for hospital use. Medical, Economic and Public Health Assessment Division 2/16 1 CHARACTERISTICS OF THE MEDICINAL PRODUCT 1.1. Active ingredient Ciprofloxacin 1.2. Indication "Antibiotic treatment for adults and children from 1 year: - for acute otitis externa - for purulent otorrhea of the mastoid cavity and chronic suppurative otitis media with tympanic perforation. Consideration should be given to official guidance on the appropriate use of antibacterial agents

Haute Autorite de sante2014

10. Ciprofloxacin

Ciprofloxacin USE OF CIPROFLOXACIN IN PREGNANCY 0344 892 0909 USE OF CIPROFLOXACIN IN PREGNANCY (Date of issue: November 2016 , Version: 3 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary The quinolones (including ciprofloxacin, levofloxacin, moxifloxacin, nalidixic acid, norfloxacin and ofloxacin) are broad (...) -spectrum synthetic antibiotics used in the treatment of a wide variety of infections including those of the urinary tract, respiratory-tract, gastro-intestinal system, bones and joints, as well as gonorrhoea, chlamydia and septicaemia. Ciprofloxacin is also used in the treatment or post-exposure prophylaxis of anthrax. No increased risk of spontaneous abortion, congenital malformations overall, low birth weight, preterm delivery, intrauterine death or neonatal complications have been found for in utero

UK Teratology Information Service2014

11. Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy--EORTC Infectiou

Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy--EORTC Infectiou 23358983 2013 03 18 2013 05 06 2014 11 20 1527-7755 31 9 2013 Mar 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Oral antibiotics for fever in low-risk neutropenic patients (...) with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV. 1149-56 10.1200/JCO.2012.45.8109 This double-blind, multicenter trial compared the efficacy and safety of a single daily oral dose of moxifloxacin with oral combination therapy in low-risk febrile neutropenic patients with cancer. Inclusion criteria were cancer, febrile neutropenia, low

EvidenceUpdates2013

12. Ciprofloxacin and loperamide in the treatment of bacillary dysentery.

Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ciprofloxacin and loperamide in t... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1993 ) Volume: 118 , Issue: 8 , Pages: 582-586 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To compare the safety and efficacy of loperamide plus ciprofloxacin with those of ciprofloxacin alone in the treatment (...) of bacillary dysentery. DESIGN: Double-blind, placebo-controlled, randomized clinical trial. SETTING: Hospital in Thailand. PARTICIPANTS: Eighty-eight adults with dysentery seeking medical care between November 1990 and February 1992. Patients who had received prior antibiotics or antimotility drugs were excluded. INTERVENTION: All 88 patients with dysentery were treated with ciprofloxacin, 500 mg twice daily for 3 days. Forty-two of these patients were randomly assigned to receive loperamide, a 4-mg

Annals of Internal Medicine2013

14. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial.

Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. 22726802 2012 08 06 2012 08 13 2016 06 23 1474-547X 380 9840 2012 Aug 04 Lancet (London, England) Lancet Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. 484-90 10.1016/S0140-6736(12)60608-4 Acute pyelonephritis is a common (...) infection in adult women, but there is a paucity of controlled trials of its treatment and the optimum duration of antibiotic treatment has not been properly defined. We compared the efficacy of ciprofloxacin for 7 days and 14 days in women with community-acquired acute pyelonephritis. In a prospective, non-inferiority trial undertaken at 21 centres of infectious diseases in Sweden, women (aged ≥18 years) who were not pregnant and had a presumptive diagnosis of acute pyelonephritis were randomly

Lancet2012

15. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial.

Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. 22318279 2012 02 09 2012 02 16 2016 10 19 1538-3598 307 6 2012 Feb 08 JAMA JAMA Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. 583-9 10.1001/jama.2012.80 Although fluoroquinolones remain the most reliable urinary antimicrobial, resistance rates have increased and effective fluoroquinolone-sparing antimicrobials are needed (...) . To determine whether cefpodoxime is noninferior to ciprofloxacin for treatment of acute cystitis. Randomized, double-blind trial of 300 women aged 18 to 55 years with acute uncomplicated cystitis comparing ciprofloxacin (n = 150) with cefpodoxime (n = 150); patients were from a student health center in Seattle, Washington, and a referral center in Miami, Florida. The study was conducted from 2005 to 2009 and outcomes were assessed at 5 to 9 days and 28 to 30 days after completion of therapy. Intent

JAMA2012 Full Text: Link to full Text with Trip Pro

16. Clinical equivalency of ciprofloxacin 750mg enterally and 400mg intravenously for patients receiving enteral feeding: systematic review

Clinical equivalency of ciprofloxacin 750mg enterally and 400mg intravenously for patients receiving enteral feeding: systematic review Clinical equivalency of ciprofloxacin 750mg enterally and 400mg intravenously for patients receiving enteral feeding: systematic review Clinical equivalency of ciprofloxacin 750mg enterally and 400mg intravenously for patients receiving enteral feeding: systematic review Chui D, Cheng L, Tejani AM CRD summary This review reported that there was insufficient (...) evidence to determine whether twice daily doses of 750mg enteral or 400mg intravenous ciprofloxacin were more effective in adult patients who received enteral feeds. Despite a risk of publication bias and lack of a validity assessment, the findings of the review appear reliable given the very limited evidence. Authors' objectives To compare the effects of 750mg enteral and 400mg intravenous ciprofloxacin for adult patients receiving enteral feeding. Searching EMBASE and MEDLINE were searched for fully

DARE.2009

17. Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections

Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections Paladino J A, Gilliland-Johnson K K, Adelman M H, Cohn S M Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study compared the cost-effectiveness of two antibiotic regimens, ciprofloxacin-metronidazole versus piperacillin-tazobactam, for the treatment of adult patients with complicated intra-abdominal infections requiring surgical intervention

NHS Economic Evaluation Database.2008

19. Cost of ciprofloxacin/dexamethasone vs amoxicillin/clavulanic acid for the treatment of acute otitis media in tympanostomy tube patients in the US

Cost of ciprofloxacin/dexamethasone vs amoxicillin/clavulanic acid for the treatment of acute otitis media in tympanostomy tube patients in the US Cost of ciprofloxacin/dexamethasone vs amoxicillin/clavulanic acid for the treatment of acute otitis media in tympanostomy tube patients in the US Cost of ciprofloxacin/dexamethasone vs amoxicillin/clavulanic acid for the treatment of acute otitis media in tympanostomy tube patients in the US Schmier J K, Waycaster C R, Wall G M Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study compared the cost-effectiveness of ciprofloxacin-dexamethasone ear drops with oral amoxicillin-clavulanic acid for the treatment of patients with acute otitis media in the tympanostomy tube (AOMT

NHS Economic Evaluation Database.2007

20. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost

Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis (...) therapy with ciprofloxacin to intravenous ceftaxidime in the treatment of spontaneous bacterial peritonitis (SBP). The switch therapy regimen involved intravenous ciprofloxacin (Ciproxin; Bayer Sp.A., Milan) administered at a dose of 200 mg twice daily (b.i.d.) for a serum creatine (SCR) level of 2.5 mg/dL, and 200 mg every 24 hours for an SCR level of greater than 2.5 mg/dL. Intravenous ciprofloxacin was followed by oral ciprofloxacin if and when clinical signs of infection had disappeared

NHS Economic Evaluation Database.2006